Do P2Y12 receptor inhibitors prescribed poststroke modify the risk of cognitive disorder or dementia? Protocol for a

Madeleine Hinwood1,2, Jenny Nyberg3, Lucy Leigh2

  • 1School of Medicine and Public Health, The University of Newcastle, Callaghan, New South Wales, Australia Madeleine.Hinwood@newcastle.edu.au.

BMJ Open
|May 9, 2022
PubMed
Abstract

Insights

This study proposes a causal analysis to investigate if P2Y12 receptor inhibitors, used after stroke, increase dementia risk by affecting brain microglia. The research uses Swedish health data to explore this potential link.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Epidemiology

Background:

  • P2Y12 receptor inhibitors are prescribed for secondary stroke prevention.
  • These inhibitors target P2Y12 receptors found on platelets and brain microglia.
  • The potential impact of these drugs on cognitive function via microglia is not fully understood.

Purpose of the Study:

  • To describe a causal approach for analyzing the risk of cognitive disorder or dementia associated with P2Y12 receptor inhibitors post-stroke.
  • To investigate the role of microglia in mediating potential adverse cognitive effects of these antiplatelet medications.
  • To utilize real-world evidence for causal inference in this clinical question.

Main Methods:

  • A cohort study nested within Swedish National Health and Medical Registers (2006-2016).
  • Utilizing directed acyclic graphs and the target trial approach for causal inference.
  • Employing time-to-event analysis with competing risks for cognitive disorder or dementia development at 1, 2, and 5-year follow-ups.

Main Results:

  • This section describes the planned analysis and data requirements for causal inference.
  • Causal effect estimates and their precision will be quantified.
  • Sensitivity analyses will be conducted to address potential biases in the real-world data.

Conclusions:

  • The study protocol outlines a rigorous causal inference framework.
  • It addresses a clinically relevant question regarding antiplatelet medication safety and cognitive health.
  • Findings will inform clinical practice and future research on stroke recovery and dementia prevention.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
659
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
270
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
184